

# Notes of the Formulary Management Group

Held on	Tuesday 6 <sup>th</sup> December 2016			Jubilee House, Room 1	
Members	Attended	Apologies	Absent	Designation	Abbreviation
	✓			Head of Medicines Management (Chair)	(C)
	✓			Prescribing Adviser	(PA)
	✓			GP Lead for Medicines Management	(GP)
	✓			WHT Pharmacist	(WHTP)
	✓			Primary Care Pharmacist	(PCP)
	✓			Clinical Nurse Specialist	(CNS)
			✓	Nurse Non-Medical Prescriber	(NNMP)
	✓			DWMHPT Pharmacist	(DWMHP)
		✓		DWMHPT Deputy Pharmacist	(DWMHDP)
			✓	Healthcare Governance	(HG)
			✓	Chief Pharmacist Walsall Healthcare Trust	(CPWHT)
			✓	Patient Representative	(PR)
		✓		Note Taker	
	✓			Work Experience with Medicines Management Team	
	✓			Homecare & Formulary Pharmacist (WHT)	
	✓			WHT	

	Agenda item	Actions
1.	<p><b><u>Welcome And Apologises (Declarations of AOB)</u></b></p> <p>Everyone was welcomed to Decembers Formulary Management group meeting.</p>	
2.	<p><b><u>Minutes Of Last Meeting</u></b> - Consent agenda accepted.</p> <p>The minutes from the last meeting in November were declared a true and accurate record.</p>	
3.	<p><b><u>Matters Arising/Actions Sheet</u></b></p> <p><b>Degludec</b> – C confirmed Dr will be attending the JMMC meeting in December to discussion any issues the committee should have regarding the drug.</p> <p><b>Ferinject</b> – The Dr presented and outlined to the committee that the drug is used with emergency patients with a known cause of anemia and will be followed up by the hospital but can be utilized by the GP. The main reasons for the change in drug was to reduce administration and nursing time costs, reduce the amount of blood transfusions and finally the drug appears safer than previous drugs subscribed to patients. C confirmed this item is now complete and will be removed from the action sheet.</p> <p><b>Action</b> – C to investigate whether the drug could be scoped in as a commissioned service.</p> <p><b>NOACs</b> – No further updates - PCP still awaiting a response from the Dr.</p> <p><b>Action</b> – The Homecare &amp; Formulary Pharmacist will be taking over this action to chase the Dr at the hospital for a response.</p> <p><b>Keele Competency Training</b> – C advised that RMOC have set up steering groups and the function is due to be operational by the end of March. Scoping exercises are also taking place with the Task and Finish groups. All concerns that were raised from the previous meeting have been passed on accordingly – C will provide the committee with an update in due course.</p> <p><b>Obesity Drugs</b> – C circulated to the committee the email response back from Public Health in regards to prescribing the medicines as part of the service and the response back was no - C confirmed this item is now complete and will be removed from the action sheet.</p>	

**Next meeting – Tuesday 7<sup>th</sup> February 2016, 1:00 – 3:30pm at Jubilee House, Room 1**

# Notes of the Formulary Management Group

	<p><b>OPEP Funding for this year</b> – No further updates - C still awaiting a response from the Community team.</p> <p><b>Esyma</b> – Currently waiting for the ESCA to be updated.</p> <p><b>Formulary Review Process</b></p> <ul style="list-style-type: none"> <li>• <b>Baby Milks Formulary</b> – C confirmed this is still on-going and no progress has been made.</li> <li>• <b>Branded Lamotrigine/Lamictal</b> – No further updates have been received due to staff members being off.</li> </ul> <p><b>Action</b> – PCP and Homecare &amp; Formulary Pharmacist to follow up and will update the committee at the next meeting.</p>	
4.	<p><b><u>Declarations of Interest</u></b></p> <p>Forms must be completed and returned back quarterly.</p>	
5.	<p><b><u>Topiramate Prescribing</u></b></p> <p>The committee agreed to take the above item to the JMMC meeting for a full discussion.</p>	
6.	<p><b><u>DWMHPT CQUINS Quarter 2</u></b></p> <p>C confirmed this item has already been discussed at the previous meeting and no further discussion was needed to take place.</p>	
7.	<p><b><u>CQUIN Report Q2 Local Prescribing – July to September 2016</u></b></p> <p>C confirmed this item has already been discussed at the previous meeting and no further discussion was needed to take place.</p>	
8.	<p><b><u>Decline to Prescribe Form – IG Safe - APC</u></b></p> <p>The committee agreed to bring back this item at Februarys Formulary meeting.</p>	
9.	<p><b><u>Partners Consultation Letter 2016</u></b></p> <p>A brief discussion took place regarding the figures provided from Walsall Council – The committee are advised to send across any responses to the chair before the closing date on the 9<sup>th</sup> December.</p>	
10.	<p><b><u>NICE Technology Appraisal</u></b></p> <ul style="list-style-type: none"> <li>• <b>Apremilast</b></li> </ul> <p>A complex discussion took place and the committee agreed to send a formal response back stating the drug has been considered and outlining the next actions from the committee. The drug will be sent to the JMMC for approval.</p> <p><b>Action</b> - Homecare &amp; Formulary Pharmacist to send the chair the contact details for the Nurse Consultant Dermatologist.</p>	
11.	<p><b><u>Non-NICE TA Drug/Devices – Full Application (JMMC Feedback)</u></b></p> <ul style="list-style-type: none"> <li>• <b>Application 142. Dulaglitide</b></li> </ul> <p>A brief discussion took place and the committee agreed to pend the application on this occasion and bring the application back to the JMMC meeting. This will allow the Dr to prepare for the types of questions the committee have to raise.</p>	

# Notes of the Formulary Management Group

12.	<p><b><u>Non – NICE TA Drug/Devices – Short Applications</u></b></p> <ul style="list-style-type: none"> <li>• <b>Application 143.Navina</b> – A complex discussion took place regarding the application and the cost differences imposed. The committee agreed to pend the application on this occasion and to bring it back at the February Formulary meeting following more insight around the patients and also to provide a pathway for the committee.</li> <li>• <b>Application 141. Nivolumab</b> - The application was not discussed at the meeting as this is a NICE tag and approved.</li> </ul>	
13.	<p><b><u>Drug Safety Update</u></b></p> <ul style="list-style-type: none"> <li>• None</li> </ul>	
14.	<p><b><u>Horizon Scanning</u></b></p> <ul style="list-style-type: none"> <li>• None</li> </ul>	
15.	<p><b><u>Appeals</u></b></p> <ul style="list-style-type: none"> <li>• None</li> </ul>	
16.	<p><b><u>Formulary Updates</u></b></p> <ul style="list-style-type: none"> <li>• <b>Application 144. Respiratory</b></li> </ul> <p>Homecare &amp; Formulary Pharmacist advised the committee that they are currently working through all the Formulary drugs using JMMC and local guidelines, the hospital is validating them all and they are then being published on the website. The next chapters to be taken forward in February are Gastro and cardiovascular.</p> <p><b><u>Action</u></b> - Homecare &amp; Formulary Pharmacist to ask Respiratory Consultant for help around Respiratory.</p>	
17.	<p><b><u>Formulary Breach</u></b></p> <ul style="list-style-type: none"> <li>• Topiramate</li> <li>• Victoza</li> <li>• Qutenza Patches</li> </ul> <p style="text-align: center;">A brief discussion took place regarding the above breaches.</p>	
18.	<p><b><u>Recommendations to JMMC</u></b></p> <p>The following applications have been recommended to the JMMC by the committee for approval:</p> <ul style="list-style-type: none"> <li>• Apremilast</li> <li>• Application 142. Dulaglitide</li> </ul>	
19.	<p><b><u>Any other business</u></b></p> <ul style="list-style-type: none"> <li>• <b>Pain Prescribing</b></li> <li>• <b>KINES – Monthly update – Oct 16</b></li> <li>• <b>KINES – Rapid Update – Bioequivalence of Anti-TNF-Alpha Biosimilar Oct 16</b></li> <li>• <b>KINES Rapid Update – Statins – Review of Evidence Oct 16</b></li> <li>• <b>KINES Public Health England – Vitamin Guidelines</b></li> <li>• <b>KINES Antipsychotics in care homes</b></li> </ul> <p>The above was not discussed at the meeting but the chair asked the committee to take a look outside.</p>	
20.	<b>Finish</b>	
<p>These minutes are a true representation of the Group's proceeding</p> <p>Signed: _____ Chair _____ Date _____</p>		

These minutes will be redacted to remove names/initials before publication

# Notes of the Formulary Management Group

## Future Meeting Dates

Formulary Management Group Future Meeting Schedule 2016								
Date	Month	Year	Venue		Date	Month	Year	Venue
					6 <sup>th</sup>	December	2016	Room1

Formulary Management Group Future Meeting Schedule 2017								
Date	Month	Year	Venue		Date	Month	Year	Venue
3 <sup>rd</sup>	January	2017	Room1		4 <sup>th</sup>	July	2017	Room1
7 <sup>th</sup>	February	2017	Room1		1 <sup>st</sup>	August	2017	Room1
7 <sup>th</sup>	March	2017	Room1		5 <sup>th</sup>	September	2017	Room1
4 <sup>th</sup>	April	2017	Room1		3 <sup>rd</sup>	October	2017	Room1
2 <sup>nd</sup>	May	2017	Room1		7 <sup>th</sup>	November	2017	Room1
6 <sup>th</sup>	June	2017	Room1		5 <sup>th</sup>	December	2017	Room1

Formulary Management Group Future Meeting Schedule 2018								
Date	Month	Year	Venue		Date	Month	Year	Venue
2 <sup>nd</sup>	January	2018	Room1		3 <sup>rd</sup>	July	2018	Room1
6 <sup>th</sup>	February	2018	Room1		7 <sup>th</sup>	August	2018	Room1
6 <sup>th</sup>	March	2018	Room1		4 <sup>th</sup>	September	2018	Room1
3 <sup>rd</sup>	April	2018	Room1		2 <sup>nd</sup>	October	2018	Room1
1 <sup>st</sup>	May	2018	Room1		6 <sup>th</sup>	November	2018	Room1
5 <sup>th</sup>	June	2018	Room1		4 <sup>th</sup>	December	2018	Room1

Next meeting – Tuesday 7<sup>th</sup> February 2016, 1:00 – 3:30pm at Jubilee House, Room 1